表紙
市場調查報告書

焦點市場分析:飲食障礙

Market Spotlight: Eating Disorders

出版商 Datamonitor Healthcare 商品編碼 633160
出版日期 內容資訊 英文 42 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
焦點市場分析:飲食障礙 Market Spotlight: Eating Disorders
出版日期: 2019年12月02日內容資訊: 英文 42 Pages
簡介

全球從10歲到19歲的女性人口飲食障礙的患病人數預測將從2017年的約3560萬人,增加到2026年的3810萬人。

與本報告提供全球飲食障礙的治療藥市場調查,彙整疾病的背景·概要,患病人數的十年預測,已上市藥物與核准趨勢,主要的開發平台概要,授權·資產收購等企業間的主要交易趨勢,主要藥物的銷售額預測,臨床試驗狀況等資料。

概要

主要的要點

疾病的背景

  • 亞型

治療

  • 心理治療
  • 藥物療法

流行病學

已上市藥物

  • 核准趨勢:各國

開發平台藥物

今後主要的活動

授權·資產收購契約

本源專利

商機

臨床試驗環境

  • 贊助商:各狀況
  • 贊助商:不同階段

文獻

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC0190350

This Market Spotlight report covers the Eating Disorders market, comprising key marketed and pipeline drugs, clinical trials, upcoming events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

Worldwide, Datamonitor Healthcare estimates that in 2017, there were approximately 35.6 million prevalent cases of eating disorders in females aged 10-19 years, including 3.0 million cases of anorexia nervosa, 11.6 million cases of bulimia nervosa, and 14.3 million cases of binge eating disorder.

In this demographic group, Datamonitor Healthcare forecasts the number of prevalent cases of eating disorders to increase to 38.1 million by

2026. Edgemont's fluoxetine tablets, Eli Lilly's Prozac, and Takeda's Vyvanse are the only FDA-approved drugs for eating disorders. These drugs are administered via the oral route, with Vyvanse also available in an intranasal formulation.

There are only two industry-sponsored drugs in active clinical development for eating disorders, with one drug each in Phase II and the NDA/BLA phase.

Therapies in development for eating disorders focus on targets such as dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, and ghrelin receptor. These drugs are administered via the oral and subcutaneous routes.

The only high-impact upcoming event in the eating disorders space is an expected PDUFA date for dasotraline. The overall likelihood of approval of a Phase I psychiatry-other asset is 10.8%, and the average probability a drug advances from Phase III is 78.6%. Drugs, on average, take 9.3 years from Phase I to approval, compared to 8.9 years in the overall psychiatry space.

There have been only three licensing and asset acquisition deals involving eating disorders drugs during 2014-19. The values were not disclosed for any of these deals.

All of the clinical trials for eating disorders have been in Phase III.

The US leads in terms of the number of eating disorders clinical trials globally, while Germany leads the major EU markets. Clinical trial activity in the eating disorders space consists entirely of completed trials. Takeda has the highest number of completed clinical trials for eating disorders, with three trials.

Takeda leads industry sponsors with the highest number of overall clinical trials for eating disorders, followed by Johnson & Johnson.

TABLE OF CONTENTS

CONTENTS

6 OVERVIEW

7 KEY TAKEAWAYS

8 DISEASE BACKGROUND

8 Subtypes

9 TREATMENT

9 Psychotherapy

9 Medications

10 EPIDEMIOLOGY

19 MARKETED DRUGS

21 PIPELINE DRUGS

25 RECENT EVENTS AND ANALYST OPINION

25 Relamorelin for Eating Disorders (June 25, 2019)

26 OPNT001 for Eating Disorders (February 21, 2019)

27 Dasotraline for Eating Disorders (July 25, 2018)

30 KEY UPCOMING EVENTS

31 PROBABILITY OF SUCCESS

32 LICENSING AND ASSET ACQUISITION DEALS

33 PARENT PATENTS

34 REVENUE OPPORTUNITY

35 CLINICAL TRIAL LANDSCAPE

36 Sponsors by status

37 Sponsors by phase

39 BIBLIOGRAPHY

39 Prescription information

41 APPENDIX

LIST OF FIGURES

  • 12 Figure 1: Trends in worldwide prevalent cases of eating disorders in females aged 10-19 years, 2017-26
  • 21 Figure 2: Overview of pipeline drugs for eating disorders in the US
  • 21 Figure 3: Pipeline drugs for eating disorders, by company
  • 21 Figure 4: Pipeline drugs for eating disorders, by drug type
  • 22 Figure 5: Pipeline drugs for eating disorders, by classification
  • 27 Figure 6: OPNT001 for Eating Disorders (February 21, 2019): Phase II - Bulimia Nervosa (U.K.)
  • 29 Figure 7: Dasotraline for Eating Disorders (July 25, 2018): Phase III - SEP360-321
  • 30 Figure 8: Key upcoming events in eating disorders
  • 31 Figure 9: Probability of success in the eating disorders pipeline
  • 32 Figure 10: Licensing and asset acquisition deals in eating disorders, 2014-19
  • 35 Figure 11: Clinical trials in eating disorders
  • 35 Figure 12: Top 10 drugs for clinical trials in eating disorders
  • 36 Figure 13: Top 10 companies for clinical trials in eating disorders
  • 36 Figure 14: Trial locations in eating disorders
  • 37 Figure 15: Eating disorders trials status
  • 38 Figure 16: Eating disorders trials sponsors, by phase

LIST OF TABLES

  • 11 Table 1: Worldwide prevalent cases of eating disorders in females aged 10-19 years, 2017-26
  • 13 Table 2: Prevalent cases of eating disorders in females aged 10-19 years in Africa, 2017-26
  • 14 Table 3: Prevalent cases of eating disorders in females aged 10-19 years in Asia, 2017-26
  • 15 Table 4: Prevalent cases of eating disorders in children aged 10-19 years in Latin America and the Caribbean, 2017-26
  • 16 Table 5: Prevalent cases of eating disorders in children aged 10-19 years in Northern America, 2017-26
  • 17 Table 6: Prevalent cases of eating disorders in children aged 10-19 years in Oceania, 2017-26
  • 18 Table 7: Prevalent cases of eating disorders in all ages in Europe, 2017-26
  • 20 Table 8: Marketed drugs for eating disorders
  • 23 Table 9: Pipeline drugs for eating disorders in the US
  • 25 Table 10: Relamorelin for Eating Disorders (June 25, 2019)
  • 26 Table 11: OPNT001 for Eating Disorders (February 21, 2019)
  • 28 Table 12: Dasotraline for Eating Disorders (July 25, 2018)
  • 33 Table 13: Parent patents in eating disorders
  • 34 Table 14: Historical global sales, by drug ($m), 2014-18
  • 34 Table 15: Forecasted global sales, by drug ($m), 2019-23
Back to Top